Newsbenzinga
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
· Published
Article summary
MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.
An excerpt from the original article.
Comments —
Loading comments…